Emerging data suggest Retatrutide , a dual stimulator targeting both GLP-1 and another hormone, could provide a notable advancement for weight treatment. Initial human trials have demonstrated considerable losses in visceral fat , possibly exceeding other obesity treatments. Nevertheless , more evaluation is necessary to thoroughly understand its r